E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Congenital Afibrinogenaemia and Severe Hypofibrinogenemia |
|
E.1.1.1 | Medical condition in easily understood language |
Deficiency of fibrinogen in human plasma and a decreased fibrinogen concentration with milder symptoms |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10052651 |
E.1.2 | Term | Afibrinogenaemia |
E.1.2 | System Organ Class | 100000004850 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To clinically evaluate the hemostatic efficacy of FIB Grifols in on-demand treatment of all documented acute bleeding episodes and in perioperative management of bleeding during and after all documented surgical procedures in subjects with congenital fibrinogen deficiency as determined by the Independent Endpoint Adjudication Committee (IEAC).
|
|
E.2.2 | Secondary objectives of the trial |
-To evaluate the hemostatic efficacy of FIB Grifols in on-demand treatment of the first documented acute bleeding episode and in perioperative management of bleeding during and after the first documented surgical procedure in subjects with congenital fibrinogen deficiency as determined by the IEAC. -To evaluate the hemostatic efficacy of FIB Grifols in on-demand treatment of the first acute bleeding episode and all acute bleeding episodes in subjects with congenital fibrinogen deficiency as determined by the principal investigator at each trial site. -To evaluate the hemostatic efficacy of FIB Grifols in perioperative management of bleeding during all surgical procedures in subjects with congenital fibrinogen deficiency as determined by the surgeon. -To evaluate the hemostatic efficacy of FIB Grifols in perioperative management of bleeding after all surgical procedures in subjects with congenital fibrinogen deficiency as determined by the principal investigator.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male or female subject between 6 to 70 years of age. 2. Signed and dated written ICF, or the subject’s parent or legal guardian signs and dates the ICF where applicable, and the Subject Authorization Form (SAF) where applicable.Pediatric subjects, as defined by local regulations, will be asked to sign an age appropriate assent form. 3. Diagnosed with congenital fibrinogen deficiency manifested as afibrinogenemia or severe hypofibrinogenemia (fibrinogen <50 mg/dL) and expected to require treatment for acute bleeding (either spontaneous or after trauma [defined as any accidental event leading to acute bleeding]), or prophylaxis of bleeding before a surgical intervention or invasive procedure. 4. Fibrinogen level < 50 mg/dL determined by Clauss method at baseline (sample drawn within 24 hours prior to infusion on Infusion 1 Day 1 Visit). 5. Female subjects of child-bearing potential must have a negative test for pregnancy blood or urine human chorionic gonadotropin (HCG)-based assay at baseline (sample drawn within 24 hours prior to infusion on Infusion 1 Day 1 Visit). a. Female subjects/partners of child-bearing potential include any female who has experienced menarche and who has not undergone successful surgical sterilization (eg, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal (post menopausal is defined as amenorrhea for >12 consecutive months or women on hormone replacement therapy with documented serum follicle stimulating hormone level <35 mIU/mL). Even women who are using oral, implanted or injectable contraceptive hormones, mechanical products such as an intrauterine device [IUD], or barrier methods (eg, diaphragm, condoms, spermicides) to prevent pregnancy, or are practicing abstinence or where their partner is sterile (eg, vasectomy), should be considered to be of child bearing potential. 6. Willing to comply with all aspects of the clinical trial protocol, including blood sampling, for the entire duration of the study. |
|
E.4 | Principal exclusion criteria |
1. Has acquired (secondary) fibrinogen deficiency. 2. Diagnosed with dysfibrinogenemia. 3. Has known antibodies against fibrinogen. 4. Has history of anaphylaxis or severe systemic response to any drug or blood-derived product. 5. Has history of intolerance to any component of the IP. 6. Documented history of immunoglobulin A (IgA) deficiency and antibodies against IgA. 7. Is a female who is pregnant, breastfeeding or, if of child-bearing potential, unwilling to practice a highly effective method of contraception (eg, oral, injectable, or implantable hormonal methods of contraception, placement of an IUD or intrauterine system,condom or occlusive cap with spermicidal foam/gel/film/cream/suppository, male sterilization, or true abstinance ) throughout the study. a. True abstinance: when this is in line with the preferred and usual lifestyle of the subject (Periodic abstinance [eg, calendar, ovulation, symptothermal,post-ovulation methods], declaration of abstinance for the duration of a trial, and withdrawal are not acceptable methods of contraception. 8. Has any medical condition which is likely to interfere with the evaluation of the IP and/or the satisfactory conduct of the clinical trial according to the investigator’s judgment. 9. Has congenital or acquired bleeding disorders other than congenital fibrinogen deficiency. 10. Has life expectancy of less than 6 months. 11. Received FRT within 21 days prior to the Screening Visit. 12. Receiving, or having received within 3 months prior to the Screening Visit of this clinical trial, any investigational drug or device. 13. Is unlikely to adhere the protocol requirements, or is likely to be uncooperative, or unable to provide a storage sample prior to IP infusion. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint is the overall clinical assessment of the hemostatic efficacy of FIB Grifols in treating all documented acute bleeding episodes or in preventing excessive bleeding during and after all documented surgical procedures according to a 4-point scale. Hemostatic efficacy will be rated as excellent, good, moderate, or none. The primary efficacy endpoint will be assessed by the IEAC. |
|
E.5.2 | Secondary end point(s) |
- Overall clinical assessment of the hemostatic efficacy of FIB Grifols in treating the first documented acute bleeding episode or in preventing excessive bleeding during and after the first documented surgical procedure according to a 4 point scale . This secondary efficacy endpoint will be assessed by the IEAC. - Overall clinical assessment of the hemostatic efficacy of FIB Grifols in treating the first acute bleeding episode as assessed by the principal investigator at each trial site according to a 4-point scale. - Overall clinical assessment of the hemostatic efficacy of FIB Grifols in treating all acute bleeding episodes as assessed by the principal investigator at each trial site according to a 4-point scale. - Clinical assessment of the hemostatic efficacy of FIB Grifols in preventing excessive bleeding intra-operatively for all surgical procedures as assessed by the surgeon (defined as the licensed medical professional performing the invasive procedure [eg, dentist]) according to a 4-point scale . - Clinical assessment of the hemostatic efficacy of FIB Grifols in preventing excessive bleeding after all surgical procedures (ie, post-operative) as assessed by the principal investigator at each trial site according to a 4-point scale. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 2 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Bulgaria |
India |
Lebanon |
Turkey |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |